Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,235 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Pulmonary Disease COPD Clear all
Completed Phase 3 Interventional Results available

A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD

NCT01313650
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
62.5/25mcg, 62.5mcg, 25mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
37
States / cities
Tucson, Arizona • Los Angeles, California • Ormond Beach, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 17, 2026, 1:55 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

NCT01072149
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate (FF)/GW642444 Inhalation Powder, placebo
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
DeLand, Florida • Orlando, Florida • Madisonville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 17, 2026, 1:55 AM EDT
Terminated Phase 3 Interventional Results available

Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)

NCT00493974
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Zileuton, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
45 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 17, 2026, 1:55 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP)

NCT06944925
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
BBT002, Placebo
Drug
Lead sponsor
Bambusa Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Bowling Green, Kentucky • Owensboro, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 17, 2026, 1:55 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Losartan in Preventing Progression of COPD

NCT00720226
View directory record Official record
Conditions
COPD, Emphysema, Chronic Bronchitis, Smoking
Interventions
Losartan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 17, 2026, 1:55 AM EDT
Completed Phase 4 Interventional Results available

Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD

NCT00754546
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Arformoterol tartrate, Placebo: Normal Saline, Treadmill Exercise, Cycle Exercise
Drug · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 17, 2026, 1:55 AM EDT
Completed Phase 1 Interventional

Mind-Body Exercise for COPD: A Pilot Study

NCT01007903
View directory record Official record
Conditions
COPD
Interventions
Tai Chi exercise
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
45 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 17, 2026, 1:55 AM EDT
Completed Phase 2 Interventional

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

NCT00808288
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive
Interventions
PF- 00610355, Placebo, Salmeterol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 80 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
30
States / cities
Fairhope, Alabama • San Diego, California • Spring Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 17, 2026, 1:55 AM EDT
Completed Not applicable Interventional

Remote Physician Care for Home Hospital Patients

NCT04080570
View directory record Official record
Conditions
Infection, Heart Failure, Chronic Obstructive Pulmonary Disease, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Remote Visit
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Oct 17, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT00510510
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
NVA237 100 µg, Placebo, NVA237 200 µg
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Glendale, Arizona • Phoenix, Arizona • Wheat Ridge, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 17, 2026, 1:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)

NCT02347774
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer, Placebo eFlow (CS) nebulizer
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
45
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 17, 2026, 1:55 AM EDT
Completed Phase 3 Interventional Results available

Tiotropium / Respimat One Year Study in COPD.

NCT00387088
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Respimat, Tiotropium
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
3,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Berkeley, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 17, 2026, 1:55 AM EDT
Completed Not applicable Interventional Results available

E-Visit for COPD and Smoking Cessation

NCT04155073
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Cigarette Smoking, Telemedicine
Interventions
smoking cessation, early COPD detection, electronic visit, Treatment As Usual
Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 17, 2026, 1:55 AM EDT
Completed Not applicable Interventional Results available

Walk On! Physical Activity Coaching

NCT02478359
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Physical Activity Coaching (Walk On!)
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
41 Years and older
Enrollment
2,707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Oct 17, 2026, 1:55 AM EDT
Completed No phase listed Observational

Innate Immune Response in COPD

NCT02637219
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Immunity, Innate, Inflammation, Bronchitis, Chronic, Toll-Like Receptors
Interventions
Not listed
Lead sponsor
VA Puget Sound Health Care System
Federal
Eligibility
50 Years to 89 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 17, 2026, 1:55 AM EDT
Completed No phase listed Observational

Screening Evaluation for Studies of Chronic Obstructive Pulmonary Disease (COPD)

NCT00889447
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 100 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 17, 2026, 1:55 AM EDT
Completed Not applicable Interventional Results available

An Intervention to Improve Function in Severe Cardiopulmonary Illness

NCT00467298
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Heart Failure
Interventions
Exercise adherence, Self-management- prevention of illness, Self-management of illness
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 17, 2026, 1:55 AM EDT
Terminated Phase 3 Interventional Results available

Simvastatin Therapy for Moderate and Severe COPD

NCT01061671
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
simvastatin, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years to 80 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 17, 2026, 1:55 AM EDT
Completed Not applicable Interventional Results available

Study of Humidified Air to Improve Mucociliary Clearance (MCC) in COPD

NCT03935932
View directory record Official record
Conditions
COPD
Interventions
nasal delivery of heated and humidified air
Device
Lead sponsor
Frank C Sciurba
Other
Eligibility
40 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 17, 2026, 1:55 AM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02570165
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Batefenterol, Umeclidinium/ Vilanterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Hialeah, Florida • Baltimore, Maryland • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 17, 2026, 1:55 AM EDT
Terminated No phase listed Interventional Results available

Vector Efficacy Cross-Over Pilot Study

NCT04263532
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Modified BiPAP A40 with Vector Algorithm (Vector), Modified BiPAP A40 with Standard of Care Settings
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
40 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 17, 2026, 1:55 AM EDT
Not listed No phase listed Observational

Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD

NCT05865184
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease, COPD Exacerbation, CHF, Congestive Heart Failure
Interventions
Data collection
Other
Lead sponsor
Sensorum Health Inc.
Industry
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 17, 2026, 1:55 AM EDT
Not listed Not applicable Interventional

Incentive Spirometry in Non-critically Ill Hospitalized Patients With Acute Respiratory Failure

NCT02873000
View directory record Official record
Conditions
Pulmonary Complication, Dyspnea, Pneumonia, COPD, CHF, Atelectasis, PE
Interventions
Incentive Spirometry
Behavioral
Lead sponsor
Jewish Hospital, Cincinnati, Ohio
Other
Eligibility
65 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 17, 2026, 1:55 AM EDT
Terminated Phase 3 Interventional

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)

NCT04636814
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CHF6001 1600µg, CHF6001 3200µg, Placebo, Roflumilast
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years and older
Enrollment
3,973 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
150
States / cities
Andalusia, Alabama • Foley, Alabama • Guntersville, Alabama + 102 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 17, 2026, 1:55 AM EDT